Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 3016

Next Previous
Drug Profile

IBI 3016

Alternative Names: IBI-3016

Latest Information Update: 06 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Developer Innovent Biologics; SanegeneBio
  • Class Antihypertensives; Small interfering RNA
  • Mechanism of Action Angiotensinogen expression modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension

Most Recent Events

  • 06 Aug 2024 Phase-I clinical trials in Hypertension (Parenteral) (NCT06501586)
  • 20 Mar 2024 Preclinical trials in Hypertension in China (Parenteral), prior to March 2023 (Innovent Biologics pipeline, March 2024)
  • 20 Mar 2024 Innovent Biologics plans a phase I trial in Hypertension in 2024 (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top